California State Teachers Retirement System raised its stake in shares of Xencor Inc. (NASDAQ:XNCR) by 11.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 67,434 shares of the biopharmaceutical company’s stock after buying an additional 7,167 shares during the period. California State Teachers Retirement System owned 0.17% of Xencor worth $1,281,000 as of its most recent filing with the SEC.
A number of other institutional investors have also bought and sold shares of XNCR. UBS Asset Management Americas Inc. increased its position in Xencor by 5.0% in the first quarter. UBS Asset Management Americas Inc. now owns 14,800 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 700 shares during the period. Metropolitan Life Insurance Co. NY increased its position in Xencor by 5.1% in the first quarter. Metropolitan Life Insurance Co. NY now owns 21,213 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 1,026 shares during the period. Strs Ohio increased its position in Xencor by 301.1% in the second quarter. Strs Ohio now owns 36,500 shares of the biopharmaceutical company’s stock valued at $693,000 after buying an additional 27,400 shares during the period. Acadian Asset Management LLC acquired a new position in Xencor during the second quarter valued at $1,317,000. Finally, Renaissance Technologies LLC acquired a new position in Xencor during the first quarter valued at $1,303,000. Hedge funds and other institutional investors own 67.72% of the company’s stock.
Xencor Inc. (NASDAQ:XNCR) traded down 0.44% during midday trading on Friday, hitting $25.06. The stock had a trading volume of 195,513 shares. Xencor Inc. has a one year low of $9.89 and a one year high of $25.64. The stock has a market cap of $1.03 billion, a PE ratio of 26.63 and a beta of 2.14. The firm has a 50 day moving average price of $22.15 and a 200 day moving average price of $16.46.
Xencor (NASDAQ:XNCR) last issued its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $1.31. The business earned $66 million during the quarter, compared to the consensus estimate of $7.43 million. Xencor had a return on equity of 22.53% and a net margin of 39.07%. Equities analysts expect that Xencor Inc. will post $0.72 EPS for the current year.
Several equities analysts have weighed in on the stock. Leerink Swann restated an “outperform” rating and set a $18.00 target price on shares of Xencor in a report on Wednesday, June 29th. Canaccord Genuity restated a “buy” rating on shares of Xencor in a report on Tuesday, June 28th. Zacks Investment Research downgraded shares of Xencor from a “buy” rating to a “hold” rating in a report on Wednesday, August 31st. Finally, Wedbush restated an “outperform” rating and set a $27.00 target price on shares of Xencor in a report on Monday, September 12th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $23.50.
In related news, Director Bruce L. A. Carter sold 3,400 shares of the business’s stock in a transaction that occurred on Monday, August 15th. The stock was sold at an average price of $22.67, for a total transaction of $77,078.00. Following the sale, the director now owns 10,000 shares of the company’s stock, valued at $226,700. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Bassil I. Dahiyat sold 45,886 shares of the business’s stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $22.06, for a total value of $1,012,245.16. Following the sale, the insider now directly owns 365,321 shares in the company, valued at approximately $8,058,981.26. The disclosure for this sale can be found here. Insiders own 4.03% of the company’s stock.
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor Inc. (NASDAQ:XNCR).
Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.